Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

8.3K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
8.3K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.3K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.3K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

349
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
349
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

422
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
422
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

1.9K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

US drug policy does not align with experts' rankings of drug harms: a multi-criteria decision analysis.

Harm reduction journal·2025
Same author

Psychedelic research must be grounded in pharmacology.

Nature neuroscience·2025
Same author

Psychedelics produce enduring behavioral effects and functional plasticity through mechanisms independent of structural plasticity.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2025
Same author

The polypharmacology of psychedelics reveals multiple targets for potential therapeutics.

Neuron·2025
Same author

Using UAS-Gal4 designer receptors exclusively activated by designer drugs to elucidate nondopaminergic modulation of methamphetamine-induced locomotion in Drosophila.

Behavioural pharmacology·2025
Same author

History of psychedelic drug science and molecular pharmacology.

International review of neurobiology·2025

Related Experiment Video

Updated: Sep 20, 2025

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

9.0K

5-HT2A receptors: Pharmacology and functional selectivity.

Benjamin R Cummins1, Gerald B Billac2, David E Nichols3

  • 1Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, Louisiana.

Pharmacological Reviews
|May 26, 2025
PubMed
Summary

Serotonin 5-HT2A receptors are key targets for psychedelic drugs, showing promise in treating psychiatric disorders. Understanding their structural interactions informs the development of novel, effective therapeutics.

More Related Videos

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.4K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.4K

Related Experiment Videos

Last Updated: Sep 20, 2025

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

9.0K
HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.4K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.4K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Serotonin 5-HT2A receptors are widespread in mammals, involved in physiology and neuropsychiatric disorders like schizophrenia.
  • These receptors are the primary target for psychedelic drugs, which activate them to produce behavioral effects.
  • Atypical antipsychotics also target 5-HT2A receptors for therapeutic purposes.

Purpose of the Study:

  • To provide a historical overview of serotonin 5-HT2A receptors.
  • To detail key structural features and motifs involved in ligand-receptor interactions.
  • To explain how these interactions influence downstream signaling pathways and inform drug discovery.

Main Methods:

  • Review of existing literature on 5-HT2A receptor pharmacology and structure.
  • Analysis of structural data on ligand-receptor interactions.
  • Discussion of structure-activity relationships for different agonist scaffolds (tryptamines, ergolines, phenylalkylamines).

Main Results:

  • 5-HT2A receptor agonists, including psilocybin and LSD, show therapeutic efficacy for depression and substance use disorders.
  • Different agonist scaffolds interact with distinct amino acid residues, leading to functionally selective outcomes.
  • Structural understanding reveals how ligands bind and modulate receptor signaling.

Conclusions:

  • Knowledge of ligand-receptor interactions at the 5-HT2A receptor is crucial for developing novel therapeutics.
  • Targeting 5-HT2A receptors offers a promising avenue for treating various psychiatric conditions.
  • Developing functionally selective drugs based on structural insights can optimize therapeutic outcomes.